A Novel Blood Proteomic Signature for Prostate Cancer

Ammara Muazzam; Matt Spick; Olivier N.F. Cexus; Bethany Geary; Fowz Azhar; Hardev Pandha; Agnieszka Michael; Rachel Reed; Sarah Lennon; Lee A. Gethings; Robert S. Plumb; Anthony D. Whetton; Nophar Geifman; Paul A. Townsend

doi:10.3390/cancers15041051

A Novel Blood Proteomic Signature for Prostate Cancer

Ammara Muazzam, Matt Spick, Olivier N.F. Cexus, Bethany Geary, Fowz Azhar, Hardev Pandha, Agnieszka Michael, Rachel Reed, Sarah Lennon, Lee A. Gethings, Robert S. Plumb, Anthony D. Whetton, Nophar Geifman, Paul A. Townsend

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.

Original language	English
Article number	1051
Journal	Cancers
Volume	15
Issue number	4
DOIs	https://doi.org/10.3390/cancers15041051
State	Published - 1 Feb 2023
Externally published	Yes

Keywords

biomarkers
clinical onset
complement cascade
prostate cancer
proteomics
SWATH-MS

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15041051

Cite this

@article{2d5eeec652cd48b8b162d417ce73b28e,

title = "A Novel Blood Proteomic Signature for Prostate Cancer",

abstract = "Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.",

keywords = "biomarkers, clinical onset, complement cascade, prostate cancer, proteomics, SWATH-MS",

author = "Ammara Muazzam and Matt Spick and Cexus, {Olivier N.F.} and Bethany Geary and Fowz Azhar and Hardev Pandha and Agnieszka Michael and Rachel Reed and Sarah Lennon and Gethings, {Lee A.} and Plumb, {Robert S.} and Whetton, {Anthony D.} and Nophar Geifman and Townsend, {Paul A.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

day = "1",

doi = "10.3390/cancers15041051",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "4",

}

TY - JOUR

T1 - A Novel Blood Proteomic Signature for Prostate Cancer

AU - Muazzam, Ammara

AU - Spick, Matt

AU - Cexus, Olivier N.F.

AU - Geary, Bethany

AU - Azhar, Fowz

AU - Pandha, Hardev

AU - Michael, Agnieszka

AU - Reed, Rachel

AU - Lennon, Sarah

AU - Gethings, Lee A.

AU - Plumb, Robert S.

AU - Whetton, Anthony D.

AU - Geifman, Nophar

AU - Townsend, Paul A.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.

AB - Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.

KW - biomarkers

KW - clinical onset

KW - complement cascade

KW - prostate cancer

KW - proteomics

KW - SWATH-MS

UR - http://www.scopus.com/inward/record.url?scp=85149121370&partnerID=8YFLogxK

U2 - 10.3390/cancers15041051

DO - 10.3390/cancers15041051

M3 - Article

C2 - 36831393

AN - SCOPUS:85149121370

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 4

M1 - 1051

ER -

A Novel Blood Proteomic Signature for Prostate Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this